{"product_id":"ipamorelin","title":"IPAMORELIN","description":"\u003ch1 data-path-to-node=\"2\"\u003eIpamorelin (RUO) | Highly Selective GH Secretagogue | ≥99% Purity\u003c\/h1\u003e\n\u003cp data-path-to-node=\"3\"\u003e\u003cb data-path-to-node=\"3\" data-index-in-node=\"0\"\u003eIpamorelin Research Grade (RUO)\u003c\/b\u003e (CAS 170851-70-4) is a premium synthetic pentapeptide and selective GHS-R1a (ghrelin receptor) agonist. Supplied as a lyophilized crystalline powder, this compound is engineered for a growth hormone (GH)-selective profile, offering negligible ACTH, cortisol, and prolactin responses compared to earlier-generation secretagogues like GHRP-2 and GHRP-6.\u003c\/p\u003e\n\u003cp data-path-to-node=\"4\"\u003eCold-chain stored and shipped directly from the USA, every batch is verified for ≥99% purity via HPLC and Mass Spectrometry.\u003c\/p\u003e\n\u003cblockquote data-path-to-node=\"5\"\u003e\n\u003cp data-path-to-node=\"5,0\"\u003e\u003cb data-path-to-node=\"5,0\" data-index-in-node=\"0\"\u003eRegulatory Disclaimer:\u003c\/b\u003e For Research Use Only (RUO). This compound is strictly restricted to in vitro and laboratory applications. Not for human or veterinary use.\u003c\/p\u003e\n\u003c\/blockquote\u003e\n\u003ch2 data-path-to-node=\"7\"\u003eProduct Specifications\u003c\/h2\u003e\n\u003ctable data-path-to-node=\"8\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eParameter\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eSpecification\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,1,0,0\"\u003e\u003cb data-path-to-node=\"8,1,0,0\" data-index-in-node=\"0\"\u003eProduct Name\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,1,1,0\"\u003eIpamorelin (Research Grade)\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,2,0,0\"\u003e\u003cb data-path-to-node=\"8,2,0,0\" data-index-in-node=\"0\"\u003eCAS Number\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,2,1,0\"\u003e170851-70-4\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,3,0,0\"\u003e\u003cb data-path-to-node=\"8,3,0,0\" data-index-in-node=\"0\"\u003ePeptide Sequence\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,3,1,0\"\u003eAib-His-D-2-Nal-D-Phe-Lys-NH2\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,4,0,0\"\u003e\u003cb data-path-to-node=\"8,4,0,0\" data-index-in-node=\"0\"\u003eMolecular Formula\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,4,1,0\"\u003e\u003cspan class=\"math-inline\" data-math=\"C_{38}H_{49}N_{9}O_{5}\" data-index-in-node=\"0\"\u003e$C_{38}H_{49}N_{9}O_{5}$\u003c\/span\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,5,0,0\"\u003e\u003cb data-path-to-node=\"8,5,0,0\" data-index-in-node=\"0\"\u003eMolecular Weight\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,5,1,0\"\u003e711.868 Da\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,6,0,0\"\u003e\u003cb data-path-to-node=\"8,6,0,0\" data-index-in-node=\"0\"\u003ePurity\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,6,1,0\"\u003e≥99% (HPLC \u0026amp; MS Verified)\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,7,0,0\"\u003e\u003cb data-path-to-node=\"8,7,0,0\" data-index-in-node=\"0\"\u003ePhysical State\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,7,1,0\"\u003eLyophilized Crystalline Powder\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,8,0,0\"\u003e\u003cb data-path-to-node=\"8,8,0,0\" data-index-in-node=\"0\"\u003eSolubility\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,8,1,0\"\u003eSoluble in water or bacteriostatic\/sterile saline\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,9,0,0\"\u003e\u003cb data-path-to-node=\"8,9,0,0\" data-index-in-node=\"0\"\u003eTarget Receptor\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"8,9,1,0\"\u003eGhrelin Receptor (GHS-R1a)\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2 data-path-to-node=\"10\"\u003eChemical Identity \u0026amp; Structural Characteristics\u003c\/h2\u003e\n\u003cp data-path-to-node=\"11\"\u003eIpamorelin (NNC 26-0161) is recognized as the first highly selective agonist of the GHS-R1a receptor. Developed through a rigorous structural-activity relationship (SAR) program, its design intentionally excludes the dipeptide Ala-Trp to eliminate the non-selective endocrine activity common in legacy secretagogues.\u003c\/p\u003e\n\u003cp data-path-to-node=\"12\"\u003eKey structural modifications include:\u003c\/p\u003e\n\u003cul data-path-to-node=\"13\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"13,0,0\"\u003e\u003cb data-path-to-node=\"13,0,0\" data-index-in-node=\"0\"\u003eAib (\u003cspan class=\"math-inline\" data-math=\"\\alpha\" data-index-in-node=\"5\"\u003e$\\alpha$\u003c\/span\u003e-aminoisobutyric acid):\u003c\/b\u003e Located at the N-terminus, this non-proteinogenic residue creates steric hindrance that induces a helical backbone conformation, protecting the peptide from rapid enzymatic hydrolysis.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"13,1,0\"\u003e\u003cb data-path-to-node=\"13,1,0\" data-index-in-node=\"0\"\u003eD-2-Nal (D-2-naphthylalanine):\u003c\/b\u003e Featuring a bulky, bicyclic naphthalene group, this residue acts as a molecular \"anchor\" in the receptor’s hydrophobic binding pocket, ensuring high-affinity binding (Ki = 2.3 nM).\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"13,2,0\"\u003e\u003cb data-path-to-node=\"13,2,0\" data-index-in-node=\"0\"\u003eD-Isomer Chirality:\u003c\/b\u003e The strategic integration of D-isomers (D-2-Nal and D-Phe) renders the peptide largely unrecognizable to endogenous proteases, effectively extending its functional half-life to approximately 2 hours in human models.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"15\"\u003eThe Selectivity Paradigm\u003c\/h2\u003e\n\u003cp data-path-to-node=\"16\"\u003eThe defining pharmacological characteristic of Ipamorelin is its distinctly \"GH-specific\" signaling profile. Unlike its predecessors, Ipamorelin achieves potent GH stimulation without inducing off-target surges in:\u003c\/p\u003e\n\u003cul data-path-to-node=\"17\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,0,0\"\u003e\u003cb data-path-to-node=\"17,0,0\" data-index-in-node=\"0\"\u003eACTH \u0026amp; Cortisol:\u003c\/b\u003e Remains negligible even at doses 200-fold higher than the effective threshold for GH release.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,1,0\"\u003e\u003cb data-path-to-node=\"17,1,0\" data-index-in-node=\"0\"\u003eProlactin:\u003c\/b\u003e Shows no meaningful elevation in established clinical models.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"17,2,0\"\u003e\u003cb data-path-to-node=\"17,2,0\" data-index-in-node=\"0\"\u003eAppetite Stimulation:\u003c\/b\u003e Does not aggressively activate the orexigenic (hunger) pathways typically associated with GHRP-6.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 data-path-to-node=\"18\"\u003eComparative Selectivity Profile: GHS-R1a Agonists\u003c\/h3\u003e\n\u003ctable data-path-to-node=\"19\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eParameter\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eIpamorelin\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eGHRP-6\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eGHRP-2\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,1,0,0\"\u003e\u003cb data-path-to-node=\"19,1,0,0\" data-index-in-node=\"0\"\u003eGH Stimulation\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,1,1,0\"\u003eHigh\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,1,2,0\"\u003eHigh\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,1,3,0\"\u003eHigh\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,2,0,0\"\u003e\u003cb data-path-to-node=\"19,2,0,0\" data-index-in-node=\"0\"\u003eACTH\/Cortisol Rise\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,2,1,0\"\u003eNone \/ Negligible\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,2,2,0\"\u003eModerate\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,2,3,0\"\u003eHigh\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,3,0,0\"\u003e\u003cb data-path-to-node=\"19,3,0,0\" data-index-in-node=\"0\"\u003eProlactin Surge\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,3,1,0\"\u003eNone \/ Negligible\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,3,2,0\"\u003eModerate\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,3,3,0\"\u003eHigh\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,4,0,0\"\u003e\u003cb data-path-to-node=\"19,4,0,0\" data-index-in-node=\"0\"\u003eAppetite Induction\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,4,1,0\"\u003eNone \/ Negligible\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,4,2,0\"\u003eHigh\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,4,3,0\"\u003eModerate\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,5,0,0\"\u003e\u003cb data-path-to-node=\"19,5,0,0\" data-index-in-node=\"0\"\u003eDesensitization Risk\u003c\/b\u003e\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,5,1,0\"\u003eLow\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,5,2,0\"\u003eModerate\u003c\/span\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cspan data-path-to-node=\"19,5,3,0\"\u003eModerate\u003c\/span\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003ch2 data-path-to-node=\"21\"\u003eResearch Context \u0026amp; Clinical Insights\u003c\/h2\u003e\n\u003cp data-path-to-node=\"22\"\u003eRecent longitudinal studies and institutional models highlight Ipamorelin's potential across several therapeutic pathways:\u003c\/p\u003e\n\u003cul data-path-to-node=\"23\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"23,0,0\"\u003e\u003cb data-path-to-node=\"23,0,0\" data-index-in-node=\"0\"\u003eMuscle Preservation:\u003c\/b\u003e In models involving subjects aged 65–80 over 12 months, daily administration correlated with a 4.2% increase in lean body mass compared to a 0.3% increase in control groups.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"23,1,0\"\u003e\u003cb data-path-to-node=\"23,1,0\" data-index-in-node=\"0\"\u003eSkeletal Geometry:\u003c\/b\u003e Evidence confirms that Ipamorelin increases Bone Mineral Content (BMC) by stimulating true geometric growth of cortical bone dimensions.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"23,2,0\"\u003e\u003cb data-path-to-node=\"23,2,0\" data-index-in-node=\"0\"\u003eNeuroprotection (2024):\u003c\/b\u003e Emerging studies in \u003ci data-path-to-node=\"23,2,0\" data-index-in-node=\"44\"\u003eNeuropharmacology\u003c\/i\u003e demonstrate reduced neuroinflammation in animal models of traumatic brain injury (TBI) modulated via GHS-R1a pathways.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"23,3,0\"\u003e\u003cb data-path-to-node=\"23,3,0\" data-index-in-node=\"0\"\u003eMetabolic Syndrome:\u003c\/b\u003e Observational models record an 11.3% reduction in visceral adipose tissue and an 18% improvement in insulin sensitivity (HOMA-IR) over a 6-month protocol.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"25\"\u003eWhy Researchers Source from Profound Aminos\u003c\/h2\u003e\n\u003cp data-path-to-node=\"26\"\u003eProfound Aminos provides the analytical transparency required for uncompromising, institutional-grade research.\u003c\/p\u003e\n\u003cul data-path-to-node=\"27\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"27,0,0\"\u003e\u003cb data-path-to-node=\"27,0,0\" data-index-in-node=\"0\"\u003eLot-Specific Transparency:\u003c\/b\u003e Every shipment is accompanied by a batch-verified Certificate of Analysis (COA) with corresponding HPLC chromatograms and Mass Spectrometry data.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"27,1,0\"\u003e\u003cb data-path-to-node=\"27,1,0\" data-index-in-node=\"0\"\u003eUSA-Based Cold-Chain Logistics:\u003c\/b\u003e To prevent thermal degradation, all peptides are stored at -20°C and shipped directly from our USA facility to ensure peak experimental potency upon arrival.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"27,2,0\"\u003e\u003cb data-path-to-node=\"27,2,0\" data-index-in-node=\"0\"\u003eEndotoxin Monitoring:\u003c\/b\u003e Vials are rigorously screened to ensure endotoxin levels fall below 1.0 EU\/mg, making them suitable for highly sensitive in vitro assays and cellular modeling.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"27,3,0\"\u003e\u003cb data-path-to-node=\"27,3,0\" data-index-in-node=\"0\"\u003eTotal Traceability:\u003c\/b\u003e End-to-end batch tracking allows principal investigators to maintain flawless quality control throughout longitudinal studies.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"29\"\u003eRegulatory \u0026amp; Compliance Status\u003c\/h2\u003e\n\u003cul data-path-to-node=\"30\"\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"30,0,0\"\u003e\u003cb data-path-to-node=\"30,0,0\" data-index-in-node=\"0\"\u003eFDA Status:\u003c\/b\u003e Ipamorelin falls under Category 2 of the FDA’s Interim Policy on Compounding due to its non-natural amino acid composition. It is \u003cb data-path-to-node=\"30,0,0\" data-index-in-node=\"142\"\u003enot\u003c\/b\u003e FDA-approved for human use or consumption.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"30,1,0\"\u003e\u003cb data-path-to-node=\"30,1,0\" data-index-in-node=\"0\"\u003eWADA Status:\u003c\/b\u003e Strictly prohibited at all times under the classification of a Growth Hormone Secretagogue.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp data-path-to-node=\"30,2,0\"\u003e\u003cb data-path-to-node=\"30,2,0\" data-index-in-node=\"0\"\u003eRUO Designation:\u003c\/b\u003e This compound is legally provided strictly for Laboratory Research Use Only.\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2 data-path-to-node=\"32\"\u003eFrequently Asked Questions (FAQ)\u003c\/h2\u003e\n\u003cp data-path-to-node=\"33\"\u003e\u003cb data-path-to-node=\"33\" data-index-in-node=\"0\"\u003eWhy is Ipamorelin frequently researched in combination with CJC-1295?\u003c\/b\u003e\u003c\/p\u003e\n\u003cp data-path-to-node=\"33\"\u003eGHRH analogs like CJC-1295 act as an \"amplifier,\" while GHS-R1a agonists like Ipamorelin act as the \"trigger.\" In research models, administering both compounds synergistically produces a GH release magnitude significantly greater than the sum of their independent effects.\u003c\/p\u003e\n\u003cp data-path-to-node=\"34\"\u003e\u003cb data-path-to-node=\"34\" data-index-in-node=\"0\"\u003eDoes Ipamorelin require a “refractory period” between administrations?\u003c\/b\u003e\u003c\/p\u003e\n\u003cp data-path-to-node=\"34\"\u003eYes. Because it triggers the release of stored GH, the pituitary gland requires a biological window to resynthesize hormone stores before an additional, maximal pulse can be successfully triggered.\u003c\/p\u003e\n\u003cp data-path-to-node=\"35\"\u003e\u003cb data-path-to-node=\"35\" data-index-in-node=\"0\"\u003eWhat are the optimal storage protocols for long-term research?\u003c\/b\u003e\u003c\/p\u003e\n\u003cp data-path-to-node=\"35\"\u003eFor maximum stability (12–24 months), the lyophilized crystalline powder must be stored in a freezer ranging from -20°C to -80°C. Keep away from light and moisture until ready for reconstitution.\u003c\/p\u003e","brand":"BioLink Analytica","offers":[{"title":"Default Title","offer_id":45054165581893,"sku":"IP10","price":59.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0729\/0060\/8069\/files\/IPAMORELIN-10_2fb5b079-6706-4007-bdc2-31c411da54bf.png?v=1785344885","url":"https:\/\/www.biolinkanalytica.com\/products\/ipamorelin","provider":"BioLink Analytica","version":"1.0","type":"link"}